Signatures that scored high included pathways associated with cellular proliferation and the BM2 subtype of human CRC, such as Myc, E2F targets and G2/M checkpoint signatures (Fig. 3a), which were significantly enriched as early as 3 days post BrafV600E induction. The gene discussed is MYC; the disease is colorectal carcinoma.